Browsing by Author "Madaswamy S Muthu"

Now showing 1 - 8 of 8

Chitosan-sodium alginate blended polyelectrolyte complexes as potential multiparticulate carrier system: Colon-targeted delivery and gamma scintigraphic imaging
(2013) Sanjay K Lanjhiyana; Pranav Bajpayee; Karthikeyan Kesavan; Sweety Lanjhiyana; Madaswamy S Muthu
Objectives: The objective of this study is to develop stable, biodegradable chitosan-sodium alginate-based dual, ionic cross-linked multiparticulate system (microbeads) of tinidazole for targeted colon delivery and sustained drug release for the treatment of amoebiasis and thereby evaluating its targeting approach through in vivo gamma scintigraphic imaging technique. Methods: The chitosan-sodium alginate-based multiparticulate system developed was producing sustained effect by virtue of its mechanical strength using double ionotropic gelation method utilizing calcium chloride and sodium sulfate as first and second cross-linkers respectively. Prepared formulations were evaluated for percent yield, drug entrapment efficiency, particle size, degree of swelling, in vitro kinetics, and in vivo targeting potentials using gamma scintigraphic imaging technique. Results: The obtained particulates were spherical, free flowing, and had a mean particle size ranging from 1.422 mm to 1.881 mm, whereas percent yield and percent drug entrapment efficiency was found to be in between 72.61 to 82.43% and 63.25 to 79.32% respectively. Conclusion: The prepared multiparticulate system showed better sustained release property and in vivo ability to target colon for drug delivery. Hence, the developed multiparticulate system could be a promising device to achieve greater site-specificity to colon. © 2013 Informa UK, Ltd.
Design of novel bioadhesive chitosan film loaded with bimetallic gold-silver nanoparticles for antibiofilm and wound healing activity
(Institute of Physics, 2023) Chandrashekhar Singh; Abhishesh Kumar Mehata; Vikas; Punit Tiwari; Aseem Setia; Ankit Kumar Malik; Sanjeev K Singh; Ragini Tilak; Madaswamy S Muthu
Microbial infections and antibiotic resistance are among the leading causes of morbidity and mortality worldwide. The bimetallic chitosan (CS)-capped gold-silver nanoparticles (CS-AuAg-NPs) were prepared by the seeded growth synthesis technique. The nanoparticles were optimized for particle size (PS), zeta potential (ZP) and antibacterial activity by Box-Behnken design at three levels and three factors. The developed CS-AuAg-NPs were polydispersed with mean hydrodynamic PS in the range of 55 - 289 nm and ZP ranges from +8.53 mV to +38.6 mV. The optimized CS-AuAg-NPs found to have a minimum inhibitory concentration and minimal bactericidal concentration of 1.625 ± 0.68 and 3.25 ± 0.74 µg ml−1 towards multidrug resistant (MDR) Staphylococcus aureus ATCC 25923 (MDR AT) and 3.25 ± 0.93 and 3.25 ± 0.86 µg ml−1 towards MDR S. aureus clinical isolate MDR1695 (MDR CI) strain, respectively. The CS-AuAg-NPs were much more effective against MDR AT and MDR CI compared to clindamycin standard. The live/dead assay of clinical isolates strain demonstrated significant reduction of bacterial cells ∼67.52 folds compared to control group in 12 h. The hemolysis study suggested that CS-AuAg-NPs were non-hemolytic and safer for application in the wound. Furthermore, CS-AuAg-NPs were distributed in the CS film, which showed 87% wound recovery after 7 d in mice model. Hence, we concluded that CS-AuAg-NPs was safer and more effective against MDR bacteria and capable of skin regeneration in the infected wound. © 2023 IOP Publishing Ltd
Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery
(Newlands Press Ltd, 2010) Manoj K Rawat; Achint Jain; Amit Mishra; Madaswamy S Muthu; Sanjay Singh
Aim: To study the effect of different types of lipid on the entrapment efficiency (EE) and physical stability of repaglinide (RG)-loaded solid lipid nanoparticles (SLNs). RG-loaded SLNs were prepared by modified solvent injection method using stearic acid (RSA), glycerol monosteratae (RGM), glyceryl behenate (RGB) and tristearin (RTS). Poloxamer F68 was used as a stabilizer. Results: SLNs were characterized by particle size, zeta-potential, EE, in vitro release, solid-state properties (differential scanning calorimetry, transmission electron microscopy and electron diffraction) and stability at 30°C/65% relative humidity for 3 months. The mean particle size and zeta-potential of RG-loaded SLNs prepared with different lipids in varying concentrations ranged from 150 to 355 nm and -21.04 ± 3.10 to -30.54 ± 2.76 mV, respectively. Conclusion: EE was found to vary with lipids in the following order: RSA < RGM < RGB < RTS. Tristearin-prepared SLNs showed a significant prolonged drug release up to 24 h. Differential scanning calorimetry and electron diffraction microphotograph results indicated that RG entrapped in the SLNs existed in an amorphous or molecular state. SLNs prepared with stearic acid, glycerol monostearate and glyceryl behenate after storage showed significant increases in particle size, polydispersity index and EE. The SLNs prepared with tristearin were stable. © 2010 Future Science Ltd.
Exosomes as a novel nanomedicine platform for personalized triple-negative breast cancer therapy
(Newlands Press Ltd, 2023) Abhishesh Kumar Mehata; Niharika Gupta; Madaswamy S Muthu
[No abstract available]
Formulation and in vitro evaluation of upconversion nanoparticle-loaded liposomes for brain cancer
(Newlands Press Ltd, 2020) Narendra; Abhishesh Kumar Mehata; Matte Kasi Viswanadh; Roshan Sonkar; Datta Maroti Pawde; Vishnu Priya; Mamata Singh; Biplob Koch; Madaswamy S Muthu
Aim: This work focused on the development of transferrin-conjugated theranostic liposomes consisting of docetaxel (DXL) and upconversion nanoparticles for the diagnosis and treatment of gliomas. Materials & methods: Upconversion nanoparticles and docetaxel-loaded theranostic liposomes were prepared by a solvent injection method. Formulations were analyzed for physicochemical properties, encapsulation efficiency, drug release, elemental analysis, cytotoxicity and fluorescence. Results: The particle size was around 200 nm with spherical morphology and an encapsulation efficiency of up to 75.93%, was achieved for liposomes with an in vitro drug release of 71.10%. The IC50 values demonstrated enhanced cytotoxicity on C6 glioma cells with targeted liposomes in comparison with nontargeted liposomes. Conclusion: Prepared theranostic liposomes may be promising for clinical validation after an in vitro and in vivo evaluation on cell lines and animals, respectively. © 2020 Future Medicine Ltd.. All rights reserved.
PTSA-induced synthesis, in silico and nano study of novel ethylquinolin–thiazolo–triazole in cervical cancer
(Taylor and Francis Ltd., 2024) Priyanka Sonker; Rupen Tamang; Abhishesh K Mehata; Manisha Nidhar; Vishal P Sharma; Vipin Kumar; Madaswamy S Muthu; Biplob Koch; Ashish K Tewari
Aim: p-Toluenesulfonic acid-(PTSA) and grinding-induced novel synthesis of ethylquinolin–thiazolo–triazole derivatives was performed using green chemistry. Materials & methods: Development of a nanoconjugate drug-delivery system of ethylquinolin–thiazolo–triazole was carried out with D-α-tocopheryl polyethylene glycol succinate (TPGS) and the formulation was further characterized by transmission electron microscopy, atomic force microscopy, dynamic light scattering and in vitro drug release assay. The effect of 3a nanoparticles was assessed against a cervical cancer cell line (HeLa) through the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the effect on apoptosis was determined. Results & discussion: The 3a nanoparticles triggered the apoptotic mode of cell death after increasing the intracellular reactive oxygen level by enhancing cellular uptake of micelles. Furthermore, in silico studies revealed higher absorption, distribution, metabolism, elimination and toxicity properties and bioavailability of the enzyme tyrosine protein kinase. Conclusion: The 3a nanoparticles enhanced the therapeutic potential and have higher potential for targeted drug delivery against cervical cancer. © 2024 Expert Publishing Science Ltd trading as Taylor & Francis.
Theranostic liposomes for cancer diagnosis and treatment: Current development and pre-clinical success
(2013) Madaswamy S Muthu; Si-Shen Feng
Liposomes are one of the effective drug delivery systems that are developed based on the nanotechnology concept. Liposomal formulation is the first nanomedicine approved by the US FDA for clinical application. Recently, the marketed liposomes and stealth liposomes have made impact for cancer therapy. In addition, a few receptor-targeted liposome products have been in different phases of clinical trials, which are yet to be marketed. In the present editorial, the advantages of vitamin E TPGS-coated liposomes over the currently available PEG-coated liposomes will be described and their great potentials for nanotheranostics for cancer imaging and therapy will be covered. © 2013 Informa UK, Ltd.
Trastuzumab-conjugated vitamin e TPGS liposomes for sustained and targeted delivery of docetaxel
(2013) Anandhkumar Raju; Madaswamy S Muthu; Si-Shen Feng
Objectives: In this study, the authors developed d-α-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS or simply TPGS) liposomes and further conjugated them to trastuzumab for controlled and targeted delivery of docetaxel (DTX) as a model hydrophobic drug. Methods: DTX-or coumarin-6-loaded liposomes were prepared by solvent injection method and characterized for size and size distribution, surface charge, surface chemistry and drug encapsulation efficiency and drug release profile. SK-BR-3 cells were employed as an in vitro model for HER2-positive breast cancer and assessed for their cellular uptake and cytotoxicity of the two liposomal formulations. In vivo pharmacokinetics (PK) was investigated in Sprague-Dawley rats. Results: The IC50 value was found to be 20.23 ± 1.95, 3.74 ± 0.98, 0.08 ± 0.4 μg/ml for the marketed preparation of DTX, TPGS liposomes and trastuzumab-conjugated TPGS liposomes, respectively after 24 h incubation with SK-BR-3 cells. In vivo PK experiments showed that i.v. administration of trastuzumab-conjugated liposomes achieved 1.9 and 10 times longer half-life, respectively than PEG-coated liposomes and DTX. The area under the curve (AUC) was increased by 3.47-and 1.728-fold, respectively. Conclusion: The trastuzumab-conjugated vitamin E TPGS-coated liposomes showed greater potential for sustained and targeted chemotherapy in the treatment of HER2 overexpressing breast cancer. © 2013 Informa UK, Ltd.